On June 26th, Gelunhui reported that Notai Biotech (688076.SH) held the twentieth meeting of the third session of the board of directors and the seventeenth meeting of the third session of the supervisory board on June 26, 2024, which approved the proposal to "use part of the raised funds to increase the capital of wholly-owned subsidiaries for the implementation of the fundraising project" and agreed that the company would use 31.9184 million yuan of the raised funds to implement the "active pharmaceutical ingredient R&D project". The company will provide the raised funds of 31.9184 million yuan to Hangzhou Nuoao Biomedical Technology Co., Ltd. (referred to as "Nuoao") in the form of capital increase. After the capital increase, the registered capital of Nuoao will increase from 100 million yuan to 131.9184 million yuan, and it will still be a wholly-owned subsidiary of the company.
诺泰生物(688076.SH)：拟将募集资金3191.84万元用于实施“原料药产品研发项目”
Notable Biology (688076.SH): Intends to use the raised funds of 31.9184 million yuan for the implementation of the active pharmaceutical ingredient product development project.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.